The abstract is read at the publisher; the summary is JClub's.
Earlier disclosure of plasma p-tau217 and NfL in a single Spain memory clinic trial increased very high-confidence etiologic Alzheimer diagnosis to 50.0% at 3 months.
- Why it matters: Evidence was limited on whether routine, earlier sharing of blood biomarker results improves diagnostic certainty and changes care plans without harming emotional well-being.
- What they did: In a randomized clinical trial (Feb–Oct 2024) with 220 participants with SCD, MCI, or mild dementia, investigators disclosed p-tau217 and NfL at 3 months versus delayed disclosure at 9 months.
- The result: At 3 months, very high-confidence etiologic diagnosis occurred in 56/112 versus 5/108 (P < .001), with earlier disclosure also linked to more symptomatic AD treatment (14.3% vs 4.6%) and fewer follow-up neuropsychological reassessments, while emotional outcomes were not worse.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.